MONTREAL, May 16, 2017 /CNW Telbec/ - Theratechnologies
Inc. (TSX: TH) is pleased to announce the election of Dale Weil as a member of its Board.
Ms. Weil brings close to 35 years of business development
experience, much of which was acquired while working with McKesson
Canada, a diversified healthcare company and the largest
pharmaceutical distributor in the country. At McKesson Canada, Ms.
Weil has held various leadership positions, most recently as senior
advisor to the president. Ms. Weil holds a Bachelor's degree in
Marine Biology and a Master's degree in Business Administration,
both from McGill University.
"I am sincerely honoured and thrilled to join Theratechnologies'
Board of Directors. I have the privilege to join as the Company is
about to potentially enter another transformational phase. I look
forward to making a meaningful contribution to the Board and to
support management in helping the Company reach new heights," said
Ms. Weil.
"The election of Dale comes at a time when business development
experience will be, more than ever, a valued asset within our
board. I am most definitely looking forward to Dale's input and to
have access to the tremendous experience she brings to our board,"
said Dawn Svoronos, Chair of the
Board, Theratechnologies Inc.
About Theratechnologies
Theratechnologies (TSX: TH) is a specialty pharmaceutical
company addressing unmet medical needs to promote healthy ageing
and an improved quality of life among HIV patients. Further
information about Theratechnologies is available on the Company's
website at www.theratech.com and on SEDAR at www.sedar.com.
Forward-Looking Information
This press release contains statements that are considered
forward-looking information ("FLI") within the meaning of
securities regulation.
The FLI in this press release relates to future events or our
future performance. The FLI are based on a number of assumptions
and are associated with a number of risks, uncertainties and other
unknown factors that may cause our actual results, levels of
activity, performance or achievements to be materially different
from those implied by the FLI. Such FLI reflects our current views
with respect to future events and is given as at May 16, 2017. We undertake no obligation and do
not intend to update or revise the FLI contained in this press
release, except as required by law.
In preparing the FLI we have assumed, among other things, the
following: (1) our increased promotional activities and presence
within the medical community will increase our patient base in
the United States and continue to
grow EGRIFTA® sales in fiscal 2017; (2) ibalizumab will be approved
in the United States as an HIV
treatment; and (3) we will have the necessary infrastructure in
place to successfully launch and commercialize ibalizumab in
the United States.
The FLI in this press release may not materialize; accordingly,
investors should not place undue reliance on it. We refer you to
the "Risk Factors" section of our Annual Information Form dated
February 7, 2017 available at
www.sedar.com and at www.theratech.com for a description of
the risks involved in the conduct of our business.
SOURCE Theratechnologies Inc.
